Speak with me

Recent changes.

Catalyst dates move. This page lists every date on the biotech catalyst calendar that has changed in the last 30 days, and every row withdrawn in that period, with the date it moved from. A row that moves keeps its identity, so a calendar subscription updates the event in place rather than adding a second one. Nothing is ever deleted quietly.

Last compiled .

WasNowLaneCompanyEventSource
11 Nov 2026ClinicalJanssen Research & Development, LLCAs of 28 August 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Ischemic Stroke; Ischemic Attack, Transient, on 15 October 2026.NCT05702034
31 Oct 2026ClinicalJanssen Research & Development, LLCAs of 28 August 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Atrial Fibrillation, on 8 December 2026.NCT05757869
18 Sept 2026ClinicalTakedaAs of 27 August 2026, Takeda estimated primary completion of a Phase 2 trial in Crohn's Disease, on 17 February 2027.NCT06233461
31 Aug 2026ClinicalUCB Biopharma SRLAs of 27 August 2026, UCB Biopharma SRL estimated primary completion of a Phase 3 trial in Stereotypical Prolonged Seizures, on 30 September 2026.NCT05077904
22 Sept 2026ClinicalMerck Sharp & Dohme LLCAs of 20 August 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Renal Cell Carcinoma, on 22 October 2026.NCT05468697
30 Aug 2026ClinicalReCode TherapeuticsAs of 19 August 2026, ReCode Therapeutics estimated primary completion of a Phase 2 trial in Cystic Fibrosis, in November 2026.NCT06237335
14 Oct 2026ClinicalGlaxoSmithKlineAs of 17 August 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in Diphtheria-Tetanus-acellular Pertussis Vaccines, on 16 September 2026.NCT07596173
30 Nov 2026ClinicalMirati Therapeutics Inc.As of 14 August 2026, Mirati Therapeutics estimated primary completion of a Phase 2 trial in Advanced Cancer, on 30 October 2026.NCT05853575